Literature DB >> 24429180

Left ventricular diastolic dysfunction in patients with dermatomyositis without clinically evident cardiovascular disease.

Han Wang1, Han-Xiong Liu, Yin-Li Wang, Xiu-Qiong Yu, Xian-Xiang Chen, Lin Cai.   

Abstract

OBJECTIVE: To assess left ventricular (LV) diastolic function in patients with dermatomyositis (DM) without clinically evident cardiovascular (CV) disease and to estimate whether there is an association between the duration of DM and LV diastolic dysfunction (LVDD).
METHODS: The study included 51 patients with DM (43 women and 8 men) who had no clinically evident CV disease and 51 age-matched and sex-matched healthy controls. Echocardiographic and Doppler studies were conducted in all patients and controls. Early diastolic flow velocity/mitral annular early diastolic velocity (E/Em) was considered a marker for diastolic dysfunction.
RESULTS: E/Em was elevated in 39 patients (76.5%) versus 27 controls (52.9%; p < 0.05). There were significant differences between patients versus control group in late diastolic flow velocity (A), E/A ratio, Em, Em/Am (mitral annular late diastolic velocity) ratio, E/Em ratio, and deceleration time (DT; p < 0.05). There was a weak correlation with disease duration between A (r = 0.373, p = 0.007), E/A ratio (r = -0.467, p = 0.001), Em (r = -0.474, p < 0.001), Em/Am ratio (r = -0.476, p < 0.001), E/Em ratio (r = 0.320, p = 0.022), and DT (r = 0.474, p < 0.001). Disease duration was associated with E/Em after controlling for age, sex, and other factors (p < 0.05).
CONCLUSION: Our study confirms a high frequency of LVDD in DM patients without evident CV disease. The association between transmitral flow alteration and disease duration may suggest a subclinical myocardial involvement with disease progression.

Entities:  

Keywords:  DERMATOMYOSITIS; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY

Mesh:

Year:  2014        PMID: 24429180     DOI: 10.3899/jrheum.130346

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Cardiac function in patients with polymyositis or dermatomyositis: a three-dimensional speckle-tracking echocardiography study.

Authors:  Yue Zhong; Wenjuan Bai; Qibing Xie; Jianhong Sun; Hong Tang; Li Rao
Journal:  Int J Cardiovasc Imaging       Date:  2017-11-22       Impact factor: 2.357

2.  Identification of characteristics of overt myocarditis in adult patients with idiopathic inflammatory myopathies.

Authors:  Yingxian Liu; Ligang Fang; Wei Chen; Yanlin Zhu; Xue Lin; Yining Wang; Xiao Li; Qian Wang; Zhenyu Liu
Journal:  Cardiovasc Diagn Ther       Date:  2020-06

3.  Electrocardiogram-Artificial Intelligence and Immune-Mediated Necrotizing Myopathy: Predicting Left Ventricular Dysfunction and Clinical Outcomes.

Authors:  Christopher J Klein; Ilke Ozcan; Zachi I Attia; Michal Cohen-Shelly; Amir Lerman; Jose R Medina-Inojosa; Francisco Lopez-Jimenez; Paul A Friedman; Margherita Milone; Shahar Shelly
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2022-09-16

Review 4.  Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies.

Authors:  Thomas Schwartz; Louise Pyndt Diederichsen; Ingrid E Lundberg; Ivar Sjaastad; Helga Sanner
Journal:  RMD Open       Date:  2016-09-27

5.  Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study.

Authors:  Aleksandra Opinc; Joanna Sarnik; Olga Brzezińska; Marcin Makowski; Anna Lewandowska-Polak; Joanna Makowska
Journal:  Rheumatol Int       Date:  2020-03-28       Impact factor: 2.631

6.  ECG Changes Through Immunosuppressive Therapy Indicate Cardiac Abnormality in Anti-MDA5 Antibody-Positive Clinically Amyopathic Dermatomyositis.

Authors:  Takashi Matsuo; Tsuneo Sasai; Ran Nakashima; Yoshihiro Kuwabara; Eri Toda Kato; Isao Murakami; Hideo Onizawa; Shuji Akizuki; Kosaku Murakami; Motomu Hashimoto; Hajime Yoshifuji; Masao Tanaka; Akio Morinobu; Tsuneyo Mimori
Journal:  Front Immunol       Date:  2022-01-07       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.